LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Experimental Drug Induces Weight Loss and Improved Insulin Resistance in Obese Monkeys

By LabMedica International staff writers
Posted on 23 Nov 2011
Print article
An experimental drug that destroys the blood vessels within white fat (adipose) tissue reduced the body weight of obese rhesus monkeys while improving their insulin resistance without causing major adverse side effects.

A population of rhesus monkeys that were obese due to overeating and lack of exercise was used to test the effects of adipotide (the ligand-directed peptidomimetic CKGGRAKDC-GG-D(KLAKLAK)2), which had been shown previously to reduce the body weight of obese mice by more than 30%.

Investigators at the University of Texas MD Anderson Cancer Center (Houston, USA) designed adipotide to bind to two receptors, ANXA2 and prohibitin, that are specific to blood vessels supplying white adipose tissue. They reported in the November 9, 2011, issue of the journal Science Translational Medicine that treatment with adipotide induced targeted apoptosis within blood vessels of white adipose tissue and resulted in rapid weight loss and improved insulin resistance. After four weeks of treatment, the obese monkeys lost on average 11% of their body weight. Lean monkeys in the control group did not lose weight, indicating that the drug’s effect may be selective for obese subjects.

Magnetic resonance imaging and dual-energy X-ray absorptiometry confirmed a 27% reduction in white adipose tissue in the treated monkeys while fat levels increased slightly in the control group.

“Most drugs against obesity fail in transition between rodents and primates,” said senior author Dr. Renata Pasqualini, professor of medicine and experimental diagnostic imaging at the MD Anderson Cancer Center. “All rodent models of obesity are faulty because their metabolism and central nervous system control of appetite and satiety are very different from primates, including humans. We are greatly encouraged to see substantial weight loss in a primate model of obesity that closely matches the human condition. Development of this compound for human use would provide a nonsurgical way to actually reduce accumulated white fat, in contrast to current weight-loss drugs that attempt to control appetite or prevent absorption of dietary fat.”

Related Links:
MD Anderson Cancer Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more